Increasing R&D initiatives and strategic partnerships by leading market players for the advancement of recombinant DNA technology are projected to fuel market expansion over the forecast period. Furthermore, research organizations are initiating programmes and granting research funding for the discovery of innovative treatments, which will boost the expansion of the recombinant DNA technology market during the projected period.
High costs and bad effects connected with gene treatments, like Cytokine Release Syndrome (CRS) or Neurological Toxicities, are important problems impeding the expansion of the recombinant DNA technology industry.
According to Coherent Market Insights' analysis, the Global Recombinant DNA Technology Market is predicted to be worth US$ 145.4 billion in 2022, with a CAGR of 7.9% during the forecast period.
Leading companies in Recombinant DNA Technology Market:
1. Thermo Fisher Scientific
The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. The company was incorporated in 1956 and is based in Waltham, Massachusetts. On December 8, 2021, thermos fisher Scientific has completed its acquisition of PPD, Inc., a leading global provider of clinical research services to the biopharma and biotech industry.
2. Merk & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck known as MSD outside the United States and Canada, on June 29’ 2022 announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for drug discovery and development.
3. Pfizer Inc.
The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19. Pfizer inc. was founded in 1849 and is headquartered in New York, New York. Pfizer in collaboration with BioNTech on November 2022 Announced their Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine.